IceCure Medical (NASDAQ:ICCM) Stock Rating Lowered by Wall Street Zen

by · The Cerbat Gem

IceCure Medical (NASDAQ:ICCM – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

ICCM has been the subject of several other reports. Zacks Research cut IceCure Medical from a “hold” rating to a “strong sell” rating in a research report on Friday, August 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $52.50.

Read Our Latest Report on ICCM

IceCure Medical Price Performance

Shares of NASDAQ:ICCM opened at $1.96 on Friday. The firm has a fifty day moving average price of $2.73 and a two-hundred day moving average price of $6.99. IceCure Medical has a one year low of $1.95 and a one year high of $42.00. The company has a market cap of $6.72 million, a price-to-earnings ratio of -0.23 and a beta of 0.45.

IceCure Medical (NASDAQ:ICCM – Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The company reported ($1.60) EPS for the quarter. IceCure Medical had a negative net margin of 427.67% and a negative return on equity of 174.26%. The firm had revenue of $0.91 million for the quarter. Equities research analysts expect that IceCure Medical will post -4.61 EPS for the current fiscal year.

About IceCure Medical

(Get Free Report)

IceCure Medical Ltd. is an Israel-based medical device company that develops minimally invasive cryoablation technology for the treatment of tumors. The company’s technology uses liquid nitrogen to freeze and destroy targeted tissue, with the goal of providing an alternative to more invasive surgical procedures.

Its primary product, the ProSense system, is designed to deliver controlled cryoablation through a thin probe inserted into a tumor under image guidance. The system has been developed for use in a range of tumor types, including breast, kidney, liver, lung and bone tumors, and has received regulatory clearances and approvals for certain indications in markets including the United States and other countries.

IceCure Medical is headquartered in Caesarea, Israel, and serves healthcare providers through commercial and distribution activities in international markets, including North America, Europe and Asia.

Featured Stories